Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.

IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Axel Rüfer, Gerhard Müllner, Oliver Fuchs, Wolfgang R Sperr, Gregor Hoermann
{"title":"Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.","authors":"Axel Rüfer, Gerhard Müllner, Oliver Fuchs, Wolfgang R Sperr, Gregor Hoermann","doi":"10.57187/s.3679","DOIUrl":null,"url":null,"abstract":"<p><p>Hereditary alpha-tryptasemia (HAT) is an autosomal dominant genetic trait affecting 4% to 6% of the general population. Hereditary alpha-tryptasemia is caused by an excess of alpha tryptase encoding TPSAB1 copy numbers on one parenteral allele, most often duplications or triplications, leading to elevated levels of basal serum tryptase. There might be a gene dosage effect between the number of additional TPSAB1 copies, the level of basal serum tryptase and the severity of clinical symptoms, including atopic, cutaneous, gastrointestinal, musculoskeletal, autonomic and neuropsychiatric manifestations. Hereditary alpha-tryptasemia is a potential risk factor for severe anaphylactic reactions. The prevalence of hereditary alpha-tryptasemia is higher in patients with systemic mastocytosis. In the diagnostic workup of patients with anaphylactic reactions and symptoms of mast cell mediator release after measurement of basal serum tryptase, it is therefore essential to screen for both the KIT D816V activating point mutation and hereditary alpha-tryptasemia by droplet digital polymerase chain reaction. Such a diagnostic approach can identify patients with hereditary alpha-tryptasemia, which may allow the avoidance of further diagnostic workup with bone marrow examination. Moreover, it can identify patients at high risk of anaphylactic reactions. So far, no targeted therapy for hereditary alpha-tryptasemia is available. Treatment for symptom control consists of H1- and H2-blockers, leukotriene antagonists and cromoglicic acid. Urticaria and anaphylaxis are especially successfully treated with the monoclonal anti-IgE-antibody omalizumab in patients with hereditary alpha-tryptasemia. H1-blockers and steroids are sufficient in emergencies. As hereditary alpha-tryptasemia is a hereditary condition, first-degree relatives with anaphylactic reactions or symptoms of mast cell mediator release should be tested for hereditary alpha-tryptasemia after measurement of basal serum tryptase.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"155 ","pages":"3679"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.3679","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Hereditary alpha-tryptasemia (HAT) is an autosomal dominant genetic trait affecting 4% to 6% of the general population. Hereditary alpha-tryptasemia is caused by an excess of alpha tryptase encoding TPSAB1 copy numbers on one parenteral allele, most often duplications or triplications, leading to elevated levels of basal serum tryptase. There might be a gene dosage effect between the number of additional TPSAB1 copies, the level of basal serum tryptase and the severity of clinical symptoms, including atopic, cutaneous, gastrointestinal, musculoskeletal, autonomic and neuropsychiatric manifestations. Hereditary alpha-tryptasemia is a potential risk factor for severe anaphylactic reactions. The prevalence of hereditary alpha-tryptasemia is higher in patients with systemic mastocytosis. In the diagnostic workup of patients with anaphylactic reactions and symptoms of mast cell mediator release after measurement of basal serum tryptase, it is therefore essential to screen for both the KIT D816V activating point mutation and hereditary alpha-tryptasemia by droplet digital polymerase chain reaction. Such a diagnostic approach can identify patients with hereditary alpha-tryptasemia, which may allow the avoidance of further diagnostic workup with bone marrow examination. Moreover, it can identify patients at high risk of anaphylactic reactions. So far, no targeted therapy for hereditary alpha-tryptasemia is available. Treatment for symptom control consists of H1- and H2-blockers, leukotriene antagonists and cromoglicic acid. Urticaria and anaphylaxis are especially successfully treated with the monoclonal anti-IgE-antibody omalizumab in patients with hereditary alpha-tryptasemia. H1-blockers and steroids are sufficient in emergencies. As hereditary alpha-tryptasemia is a hereditary condition, first-degree relatives with anaphylactic reactions or symptoms of mast cell mediator release should be tested for hereditary alpha-tryptasemia after measurement of basal serum tryptase.

遗传性α -胰蛋白酶血症-严重过敏反应的潜在原因和肥大细胞疾病的修饰剂。
遗传性α -胰蛋白酶血症(HAT)是一种常染色体显性遗传性状,影响4%至6%的普通人群。遗传性α -胰蛋白酶血症是由编码一个肠外等位基因TPSAB1拷贝数的α -胰蛋白酶过量引起的,最常见的是重复或三次重复,导致基础血清胰蛋白酶水平升高。额外TPSAB1拷贝数、基础血清胰蛋白酶水平与临床症状(包括特应性、皮肤、胃肠道、肌肉骨骼、自主神经和神经精神表现)的严重程度之间可能存在基因剂量效应。遗传性α -胰蛋白酶血症是严重过敏反应的潜在危险因素。遗传性α -胰蛋白酶血症在全身性肥大细胞增多症患者中发病率较高。因此,在基础血清胰蛋白酶测定后出现过敏反应和肥大细胞介质释放症状的患者的诊断工作中,采用液滴数字聚合酶链反应筛查KIT D816V活化点突变和遗传性α -胰蛋白酶血症是必要的。这种诊断方法可以识别遗传性α -胰蛋白酶血症患者,这可以避免进一步的骨髓检查诊断工作。此外,它还可以识别过敏反应高危患者。到目前为止,还没有针对遗传性α -胰蛋白酶血症的靶向治疗方法。治疗症状控制包括H1和h2阻滞剂,白三烯拮抗剂和甘油三酸。遗传性α -色氨酸血症患者使用单克隆抗ige抗体omalizumab治疗荨麻疹和过敏反应尤其成功。h1受体阻滞剂和类固醇在紧急情况下就足够了。由于遗传性α -胰蛋白酶血症是一种遗传性疾病,有过敏反应或肥大细胞介质释放症状的一级亲属应在基础血清胰蛋白酶测定后检测遗传性α -胰蛋白酶血症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Swiss medical weekly
Swiss medical weekly 医学-医学:内科
CiteScore
5.00
自引率
0.00%
发文量
0
审稿时长
3-8 weeks
期刊介绍: The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信